Targets › DTPA
1 program from 1 company in 1 trial: 1 Phase 4; Other; next expected readout Jan 2028.
Open in Phaseline: the race on DTPA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Northwestern University | Gadavist 2Ml Solution for Injection gadolinium-based contrast agent (gadopentetate dimeglumine) | DTPA | Phase 4 | Image, Body | Jan 2028 |
Image, Body (1)
small molecule (1)
Northwestern University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.